The past decade has been a game-changing one for Vertex Pharmaceuticals (NASDAQ: VRTX). The biotech won approval for its ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The company's blood disorders treatment -- Casgevy -- also is a multibillion-dollar opportunity, according to Vertex. The drug launch unfolded last year, and since treatment involves a lengthy ...

Vertex's Journavx, a new non-opioid pain drug, lands Tier 3 on Optum Rx formularies. Vertex reports $2.91 billion Q4 sales.

Vertex Pharmaceuticals (NasdaqGS:VRTX) announced that its cystic fibrosis treatment, ALYFTREK®, had received regulatory approval from the UK's MHRA, a significant milestone in expanding its market ...

The FDA has lost no time in approving Vertex Pharma and CRISPR Therapeutics pioneering gene-editing therapy Casgevy for its second use, approving the drug for transfusion-dependent beta ...

So the amount of the benefit to Vertex will depend on the rate of ALYFTREK's growth and switching during the year. Offsetting that is margin pressure from CASGEVY, which is very early in its ...

In addition, Vertex's royalty burden is lower with Alyftrek than with its older CF therapies. Gene-editing therapy Casgevy has been approved for over a year in treating sickle cell disease and ...